Another day, another torment. The same will follow the next day — the excruciating pain, inexplicable fatigue, and never-ending drowsiness.
This is life with lupus, a rare, chronic autoimmune condition where the body’s immune system starts working against itself. The situation is such that the body gets into an internal battle, every day, for the rest of its days.
The word originates from Latin, which literally translates to ‘wolf’. The malar rash caused by lupus is one of its main symptoms. They look like circular discs and typically appear on the face on either side of the nose.
In the past when research was limited, people used to assume the inflicted person has been bitten by a wolf, thus derivation of the name.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.
